Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology

dc.contributor.authorSpracklen, Cassandra N.
dc.contributor.authorKaraderi, Tugce
dc.contributor.authorYaghootkar, Hanieh
dc.contributor.authorSchurmann, Claudia
dc.contributor.authorFine, Rebecca S.
dc.contributor.authorKutalik, Zoltan
dc.contributor.authorMohlke, Karen L.
dc.date.accessioned2026-02-06T18:36:17Z
dc.date.issued2019
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractCirculating levels of adiponectin, an adipocyte-secreted protein associated with cardiovascular and metabolic risk, are highly heritable. To gain insights into the biology that regulates adiponectin levels, we performed an exome array meta-analysis of 265,780 genetic variants in 67,739 individuals of European, Hispanic, African American, and East Asian ancestry. We identified 20 loci associated with adiponectin, including 11 that had been reported previously (p < 2 x 10(-7)). Comparison of exome array variants to regional linkage disequilibrium (LD) patterns and prior genome-wide association study (GWAS) results detected candidate variants (r(2) > .60) spanning as much as 900 kb. To identify potential genes and mechanisms through which the previously unreported association signals act to affect adiponectin levels, we assessed cross-trait associations, expression quantitative trait loci in subcutaneous adipose, and biological pathways of nearby genes. Eight of the nine loci were also associated (p < 1 x 10(-4)) with at least one obesity or lipid trait. Candidate genes include PRKAR2A, PTH1R, and HDAC9, which have been suggested to play roles in adipocyte differentiation or bone marrow adipose tissue. Taken together, these findings provide further insights into the processes that influence circulating adiponectin levels.
dc.description.sponsorshipNovo Nordisk Foundation Center for Basic Metabolic Research; NHGRI [F31 HG009850]; European Research Council [323195: GLUCOSEGENES-FP7-IDEAS-ERC]; NHLBI [T32 HL007055, T32 HL129982]; Novo Nordisk Foundation Center for Protein Research [NNF17OC0027594, NNF14CC0001]; Danish Council for Independent Research [DFF -6110-00183]; Novo Nordisk Foundation [NNF17OC0026848]; Li Ka Shing Foundation; WT-SSI/John Fell funds; NIHR Biomedical Research Centre, Oxford; NIH [R01DK072193, R01DK093757]; National Institute of Health Research Senior Investigator; Dutch Science Organization (ZonMW-VENI Grant) [916.14.023, R01DK089256, R01HD057194, U01HG007416, R01DK101855]; AHA [13GRNT16490017]; National Institutes of Health [5T32GM67553]; Academy of Finland Center of Excellence in Complex Disease Genetics [312062]; Academy of Finland [285380]; Finnish Foundation for Cardiovascular Research; American Heart Association [15POST24470131, 17POST33650016, U54GM115428]; National Institute of General Medical Sciences; Wellcome Trust [WT083442AIA]; Diabetes UK RD Lawrence fellowship [17/0005594, KL2TR001109]; MRC [MC_UU_12015/1] Funding Source: UKRI; Medical Research Council [MC_UU_12015/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0617-10149] Funding Source: researchfish; NNF Center for Basic Metabolic Research [Kilpeläinen Group, Hansen Group] Funding Source: researchfish; Novo Nordisk Fonden [NNF17OC0027594] Funding Source: researchfish; Novo Nordisk Foundation Center for Protein Research [PI Søren Brunak] Funding Source: researchfish; National Heart Lung and Blood Institute [T32HL129982, T32HL007055] Funding Source: NIH RePORTER; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK093757, P30DK056350, R01DK072193, P30DK020572] Funding Source: NIH RePORTER; National Institute of General Medical Sciences [U54GM115428] Funding Source: NIH RePORTER; American Heart Association (AHA) [17POST33650016, 13GRNT16490017, 15POST24470131] Funding Source: American Heart Association (AHA)
dc.description.sponsorshipJ.B.-J. and T.H. were partially funded by the Novo Nordisk Foundation Center for Basic Metabolic Research, an independent Research Center at the University of Copenhagen. R.S.F. was supported by NHGRI F31 HG009850. T.M.F. was supported by the European Research Council (grant 323195: GLUCOSEGENES-FP7-IDEAS-ERC). H.M.H. was supported by NHLBI T32 HL007055 and T32 HL129982. T.K. was supported by the Novo Nordisk Foundation Center for Protein Research (grants NNF17OC0027594 and NNF14CC0001). T.O.K. was supported by the Danish Council for Independent Research (grant DFF -6110-00183) and the Novo Nordisk Foundation (grant NNF17OC0026848). C.M.L. is supported by the Li Ka Shing Foundation, WT-SSI/John Fell funds, the NIHR Biomedical Research Centre, Oxford, Widenlife, and NIH (grant 5P50HD028138-27). M.I. McCarthy is a Wellcome Trust Senior Investigator (grant WT098381) and a National Institute of Health Research Senior Investigator, and the views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. J.B. Meigs is supported by NIH K24 DK080140. K.L.M. was supported by NIH R01DK072193 and R01DK093757. D.M.-K. is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). K.E.N. was supported by NIH R01DK089256, R01HD057194, U01HG007416, and R01DK101855 and AHA 13GRNT16490017. C.K.R. was supported by National Institutes of Health (grant 5T32GM67553). S.R. was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (grant 312062) and the Academy of Finland (grant 285380). V.S. was supported by the Finnish Foundation for Cardiovascular Research. C.N.S. was supported by the American Heart Association Postdoctoral Fellowships 15POST24470131 and 17POST33650016. J.G.W. is supported by U54GM115428 from the National Institute of General Medical Sciences. L.B.L.W. was supported by Wellcome Trust (WT083442AIA). H.Y. was funded by Diabetes UK RD Lawrence fellowship (grant 17/0005594). K.L.Y. was supported by KL2TR001109.
dc.identifier.doi10.1016/j.ajhg.2019.05.002
dc.identifier.endpage28
dc.identifier.issn0002-9297
dc.identifier.issn1537-6605
dc.identifier.issue1
dc.identifier.orcid0000-0001-7999-5538
dc.identifier.orcid0000-0001-9772-4344
dc.identifier.orcid0000-0002-0370-1473
dc.identifier.orcid0000-0003-4282-1344
dc.identifier.orcid0000-0002-8944-1771
dc.identifier.orcid0000-0002-0933-2410
dc.identifier.orcid0000-0002-2374-9204
dc.identifier.pmid31178129
dc.identifier.scopus2-s2.0-85068057969
dc.identifier.scopusqualityQ1
dc.identifier.startpage15
dc.identifier.urihttps://doi.org/10.1016/j.ajhg.2019.05.002
dc.identifier.urihttps://hdl.handle.net/11129/12273
dc.identifier.volume105
dc.identifier.wosWOS:000473723000003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherCell Press
dc.relation.ispartofAmerican Journal of Human Genetics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectGenome-Wide Association
dc.subjectAdipose-Tissue
dc.subjectPlasma Adiponectin
dc.subjectCirculating Adiponectin
dc.subjectGlycemic Traits
dc.subjectCandidate Genes
dc.subjectRare
dc.subjectDisease
dc.subjectMetaanalysis
dc.subjectExpression
dc.titleExome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology
dc.typeArticle

Files